Hashan A.’s Post

Modern therapies require modern CDMOs. In this article, Pharma Manufacturing profile 4 young companies: 👉 INCOG BioPharma Services 👉 Cellares 👉 ten23 health 👉 Matica Biotechnology, Inc. All of these companies were launched, built and nurtured with intention. As a result, they have become key players among a new generation of CDMOs, well-positioned to boldly forge the future of pharma. Read the article below ⤵️ #CDMO #ContractManufacturing #ContractDevelopment

🧬 The first and last name in scientific Discovery 💊 I am excited to see the positive impact we will have for our customers: ➡️ Removing friction from research processes ➡️ Bringing ever larger datasets within easier reach ➡️ Using mechanistic modelling to explore the previously unexplorable ➡️ Positively exploiting AI to iterate quickly towards suggesting only those solutions that we know will be safe and highly efficacious across many diverse populations

Modern therapies require modern CDMOs. In this article, Pharma Manufacturing profile 4 young companies: 👉 INCOG BioPharma Services 👉 Cellares 👉 ten23 health 👉 Matica Biotechnology, Inc. All of these companies were launched, built and nurtured with intention. As a result, they have become key players among a new generation of CDMOs, well-positioned to boldly forge the future of pharma. Read the article below ⤵️ #CDMO #ContractManufacturing #ContractDevelopment

𝐋𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐔𝐭𝐬𝐚𝐯: 𝐃𝐚𝐲 21 Wasn’t feeling well today, but still managed to finish a project titled: "𝐇𝐲𝐩𝐨𝐭𝐡𝐞𝐬𝐢𝐬 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: 𝐃𝐫𝐮𝐠 𝐒𝐚𝐟𝐞𝐭𝐲" 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰: GlobalXYZ, a pharma company, ran a drug trial, and I analyzed their dataset to check if adverse reactions were significant. 𝐔𝐬𝐞𝐝 𝐙-𝐭𝐞𝐬𝐭 𝐟𝐨𝐫 𝐩𝐫𝐨𝐩𝐨𝐫𝐭𝐢𝐨𝐧𝐬 and 𝐌𝐚𝐧𝐧-𝐖𝐡𝐢𝐭𝐧𝐞𝐲 𝐔 𝐭𝐞𝐬𝐭 𝐭𝐨 𝐬𝐞𝐞 𝐢𝐟 𝐭𝐡𝐞 𝐝𝐫𝐮𝐠 𝐠𝐫𝐨𝐮𝐩 𝐡𝐚𝐝 𝐦𝐞𝐚𝐧𝐢𝐧𝐠𝐟𝐮𝐥 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬 in adverse effects compared to the placebo group. Today's XP: 1500 And that’s it. See you tomorrow! Just some rest day for today 👋 #LearningUtsav #DatacampDonates #DataNexus2024 #LUD21 #FeativalOfLearning

We’re pleased to announce that Caitlyn Krebs, our Co-Founder and CEO, will be presenting at the BIO Investor Forum by the Biotechnology Innovation Organization in San Francisco this week. She’ll be discussing how Nalu Bio has identified a unique opportunity at the intersection of two emerging fields: The Endocannabinoid System (ECS)—the body’s natural balancing mechanism—and its application to essential health needs such as pain management. By combining our expertise in cannabinoid science with a pharmaceutical approach, we’re developing non-intoxicating molecules precisely tailored to unlock the untapped potential of the ECS and deliver scalable solutions that set a new standard for health and wellness. 🗓 When: October 16 at 1:30 p.m. 📍 Where: California Room, Fairmont Hotel, San Francisco Join us to learn more about our progress in tackling one of the most vital health challenges of our time—non-addictive pain therapeutics that provide sustained relief with the ambition to displace opioids. For more information about the event: https://lnkd.in/dZf3Myxg #BIOInvestorForum #DrugDiscovery #PainManagement #OpioidAlternatives #ChronicPain #PharmaAI

Chemaxon and Certara finally as one company, bringing you the next generation of a more precise, model-informed Drug Discovery and Development, with improved certainty in decision-making throughout. Join us for a live webinar on 20th Nov with Certara's CEO William Feehery and Chemaxon's CEO Richard Jones to learn more and be sure to check out our press release below

Pitt Street Research publishes an initiation report on Dimerix Limited - a clinical stage drug developer which is developing DMX-200 for kidney diseases. DMX-200 is in a Phase 3 trial for FSGS (Focal Segmental Glomerulosclerosis) and has completed a Phase 2 study for diabetic kidney disease. The company is expecting initial analysis in mid-March and could submit for conditional marketing approval in CY24, subject to successful results. It has secured a licensing deal with Advanz Pharma that could bring A$230m in milestone payments, plus royalties on sales. Notwithstanding all this, it is still priced like a Phase 2 company - we value DXB was A$0.58 per share in our base case scenario and A$0.77 in our bull case scenario, equating to equity values of A$246.3m and A$326.3m which are more in line with the valuation of ASX biotechs at Phase 3. Please be advised that this report is General Advice only and is a report commissioned by the Company. Please see p.20 for the key risks and the final page for the full General Advice Warning, disclosures and disclaimers. Marc Kennis Stuart Roberts Mark Diamond Nina Webster Hugh Alsop Clinton Snow Sonia Poli Hamish George #dimerix #dxb200 #kidneyhealth #kidneydisease #biotech #biotechs #biotechstocks #healthstocks #ASX #equities #equityresearch #researchreport #researchinitiation https://lnkd.in/eyjWtZ8T

Pitt Street Research publishes an initiation report on Dimerix Limited - a clinical stage drug developer which is developing DMX-200 for kidney diseases. DMX-200 is in a Phase 3 trial for FSGS (Focal Segmental Glomerulosclerosis) and has completed a Phase 2 study for diabetic kidney disease. The company is expecting initial analysis in mid-March and could submit for conditional marketing approval in CY24, subject to successful results. It has secured a licensing deal with Advanz Pharma that could bring A$230m in milestone payments, plus royalties on sales. Notwithstanding all this, it is still priced like a Phase 2 company - we value DXB was A$0.58 per share in our base case scenario and A$0.77 in our bull case scenario, equating to equity values of A$246.3m and A$326.3m which are more in line with the valuation of ASX biotechs at Phase 3. Please be advised that this report is General Advice only and is a report commissioned by the Company. Please see p.20 for the key risks and the final page for the full General Advice Warning, disclosures and disclaimers. Marc Kennis Stuart Roberts Mark Diamond Nina Webster Hugh Alsop Clinton Snow Sonia Poli Hamish George #dimerix #dxb200 #kidneyhealth #kidneydisease #biotech #biotechs #biotechstocks #healthstocks #ASX #equities #equityresearch #researchreport #researchinitiation

At the BIO Investor Forum in SF today. Looking forward to connect with investors and strategic Pharma partners as we gear up to deliver on the next value inflections in our drug discovery journey

Antibiotics are used to treat BV and UTI, but recurrences are common. Antibiotics inhibit or kill the bacteria that cause these conditions, but and they do not prevent recurrence since they do not restore protective Lactobacillus. To address this unmet medical need, Osel developed a proprietary Live Biotherapeutic Product (LBP), called LACTIN-V that contains the protective vaginal strain, Lactobacillus crispatus CTV-05. L. crispatus CTV-05 produces lactic acid and hydrogen peroxide, adheres to vaginal epithelial cells, and antagonizes bacteria associated with BV and uropathogenic E. coli, which is responsible for most UTIs. LACTIN-V has also been shown to reduce preterm birth.